1260612-13-2
1260612-13-2
Chemical Structure
SAR-260301
- CAS No.: 1260612-13-2
- Formula:C19H22N4O3
- Molecular Weight:354.40
IUPAC Name: (S)-2-(2-(2-methylindolin-1-yl)-2-oxoethyl)-6-morpholinopyrimidin-4(1H)-one
InChIKey: UAXHPOBBKRWJGA-ZDUSSCGKSA-N
SMILES: O=C1N=C(CC(N2[C@@H](C)CC3=C2C=CC=C3)=O)NC(N4CCOCC4)=C1
Biological Activity: SAR-260301 is an orally available and selective PI3Kβ inhibitor with an IC50 of 23 nM[1][2].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SAR-260301 | 99.95% | SAR-260301 is an orally available and selective PI3Kβ inhibitor with an IC50 of 23 nM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Certal V, et al. Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers. J Med Chem. 2014 Feb 13;57(3):903-20. [Content Brief]
- [2]. Bonnevaux H, et al. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor. Mol Cancer Ther. 2016 Jul;15(7):1460-71. [Content Brief]
Keywords
